Lipid-modifying agents, from statins to PCSK9 inhibitors
Mendelian randomization studies and randomized trials have conclusively demonstrated that lower LDL-cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL-cholesterol lowering treatment. Data from over 25 cardiovascular outcome trials confirm tha...
| Autori principali: | , , , |
|---|---|
| Natura: | Journal article |
| Lingua: | English |
| Pubblicazione: |
American College of Cardiology
2020
|